Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T13168 | TLR7 agonist 1 | TLR | Immunology/Inflammation |
TLR7 agonist 1 is a selective and oral TLR7 agonist (IC50: 90 nM). | |||
T5561 |
TLR7/8 agonist 1 dihydrochloride
TLR7/8 agonist-5d,二盐酸TLR7/8 agonist 1 |
TLR | Immunology/Inflammation |
TLR7/8 agonist 1 dihydrochloride (TLR7/8 agonist-5d) 是 toll 样受体TLR7/TLR8的双重激动剂。 | |||
T4258 |
TLR7 agonist 2
TLR7-agonist-1,TLR7-IN-1 |
TLR | Immunology/Inflammation |
TLR7 agonist 2 (TLR7-IN-1) 是选择性 Toll 样受体 7 激动剂,LEC 值为 0.4 μM。 | |||
T8316 |
1V209
TLR7 agonist T7 |
TLR | Immunology/Inflammation |
1V209 (TLR7 agonist T7) 是一种 Toll 样受体 7 (TLR7) 激动剂,可与各种多糖缀合,以改善其水溶性,增强功效并保持低毒性,具有抗肿瘤作用。 | |||
T71108 |
TLR7/8 agonist 1
|
||
TLR7/8 agonist 1是一种 toll 样受体 (TLR7)/TLR8的双重激动剂。 | |||
T15371 |
Gardiquimod
|
TLR; HIV Protease | Immunology/Inflammation; Microbiology/Virology; Proteases/Proteasome |
Gardiquimod 可抑制巨噬细胞和活化的外周血单个核细胞的HIV-1感染。 它是一种咪唑喹啉类似物,是一种 TLR7/8 激动剂。 | |||
T72253 |
AXC-715 trihydrochloride
T785 trihydrochloride |
TLR | Immunology/Inflammation |
AXC-715 trihydrochloride (T785 trihydrochloride) 是一种 TLR7/TLR8 双激动剂, 可用于合成抗体佐剂免疫偶联物。偶联物多为程序性死亡配体 1 (PD-L1) 连接到一个或多个佐剂的抗体结构上。 | |||
T6964 |
Resiquimod
R848,雷西莫特,S28463 |
HCV Protease; TLR | Immunology/Inflammation; Microbiology/Virology; Proteases/Proteasome |
Resiquimod (R848) 是一种 Toll 样受体7/8的激动剂,可诱导细胞因子上调。 | |||
T60894 |
TLR7/8 agonist 4
|
||
TLR7/8 agonist 4 (compound 41) 是具有抗癌活性的,TLR7/8 的有效激动剂。 | |||
T78085 |
Guretolimod hydrochloride
DSP-0509 hydrochloride |
||
Guretolimod hydrochloride为Toll-like receptor7(TLR7)的激动剂。 | |||
T79068 | TLR7/8 agonist 8 | ||
TLR7/8 agonist 8(compound 24m)是一种高效的TLR7/8双重激动剂,对hTLR7和hTLR8的EC50值分别为27 nM和12 nM。该化合物能增强PD-1/PD-L1阻断剂的抗癌效果。 | |||
T74468 |
MC-Val-Cit-PAB-Amide-TLR7 agonist 4
|
||
MC-Val-Cit-PAB-Amide-TLR7 agonist 4 (example 15) 是一种 HER2-TLR7和 HER2-TLR8免疫激动剂复合物。 | |||
T77890 |
TLR7/8 agonist 4 hydroxy-PEG6-acid hydrochloride
|
||
TLR7/8 agonist 4hydroxy-PEG6-acid hydrochloride为一种用于抗体药物偶联体(ADC)的药物-连接子偶联物。该化合物为TLR7/8 agonist 4hydroxy-PEG6-acid的盐酸盐形式,由TLR7/8 agonist 4与连接子 Hydroxy-PEG6-acid构成,适用于ADC合成。 | |||
T80976 | TLR7/8 agonist 4 hydroxy-PEG6-acid | ||
TLR7/8 agonist 4hydroxy-PEG6-acid 为ADC药物-连接子偶联物(Drug-Linker Conjugates for ADC)。该合成物结合了TLR7/8 agonist 4与连接子hydroxy-PEG6-acid,专门用于ADC合成。 | |||
T79749 | TLR7 agonist 14 | ||
TLR7 agonist14(compound 17b)作为一种TLR7激动剂,具有高效性,其EC50值为59 nM。在低纳摩尔级别浓度下,TLR7 agonist14能有效激活小鼠巨噬细胞以及hPBMC。 | |||
T61260 |
Ruzotolimod
|
||
Ruzotolimod, an agonist of TLR7, exhibits promising potential for investigating HBV, COVID-19, and SARS-CoV-2 infections (WO2021130195A1)[1]. | |||
T70965 | GSK-2245035 maleate | ||
GSK-2245035 maleate is a selective Toll-like receptor 7 (TLR7) agonist with preferential Type-1 interferon (IFN)-stimulating properties. | |||
T75213 | TLR7 agonist 12 | ||
TLR7 agonist12 (example 20) 是一种针对惰性淋巴系统恶性肿瘤具有广泛抗肿瘤活性的TLR7激动剂及嘌呤核苷类似物。其抗癌机制主要通过抑制DNA合成和诱导细胞凋亡(apoptosis)来实现。 | |||
T40152 | AXC-715 hydrochloride | ||
AXC-715 hydrochloride is a TLR7/TLR8 dual agonist, can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody construct that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants. | |||
T11482 | GSK2245035 | Others | Others |
GSK2245035 is a highly selective intranasal TLR7 agonist with preferential Type-1 interferon (IFN)-stimulating properties (pEC50s: 9.3 and 6.5 for IFNα and TFNα). It effectively suppresses allergen-induced Th2 cytokine production in human peripheral blood | |||
T61601 | TLR7/8 antagonist 2 | ||
TLR7/8 antagonist 2 (Compound 15) is a highly potent and orally active agonist of TLR7/8, exhibiting IC50 values of 4.9 and 0.6 nM for TLR7 and TLR8, respectively. Its strong affinity for these receptors makes it a promising candidate for the treatment and investigation of autoimmune diseases, including lupus erythematosus, which is associated with inappropriate activation of TLR7 and TLR8. Consequently, TLR7/8 antagonist 2 represents a valuable tool for research in the field of autoimmune disea... | |||
T79751 | TLR7 agonist 16 | ||
TLR7 agonist16 (compound 16d)为一种高效的TLR7激动剂,具有EC50值为59 nM。在低纳摩尔水平上,它可以有效激活小鼠巨噬细胞和hPBMC。 | |||
T82515 |
E104
|
||
E104(compound 1)为一种高效且选择性的TLR7激动剂,适用于ADC合成,以激发显著的抗癌活性。该化合物能够诱导小鼠巨噬细胞与hPBMC的活化。 | |||
T62178 | TLR7/8 antagonist 1 | ||
TLR7/8 Antagonist 1 (Compound 16c) 是一种咪唑喹啉衍生物,是一种有效的 TLR7/8 激动剂,对 TLR7 和 TLR8 的 IC50 值分别为 3.91 和 2.19 μM。其中 Toll 样受体 (TLR) 7 和 8 是一种治疗传染病、癌症和自身免疫性疾病的免疫调节药物开发的关键靶点。 | |||
T79877 |
MTvkPABC-P5
|
||
MTvkPABC-P5d,作为TLR7激动剂,属于免疫刺激剂类。该化合物主要应用于合成免疫刺激抗体偶联物(ISAC)。 | |||
T61110 | UC-1V150 | ||
UC-1V150 is a distinct TLR7 agonist, which activates cellular immune responses and exhibits anti-tumor effects. It also serves as a precursor for the synthesis of ISAC molecules, known as immune-stimulating antibody conjugates [1] [2]. | |||
T79750 | TLR7 agonist 15 | ||
TLR7 agonist15(compound 16b)作为一种高效的TLR7激动剂,其EC50值为59 nM。在低纳摩尔浓度下,该化合物能够有效诱导小鼠巨噬细胞和hPBMC的激活。 | |||
T5499 |
gardiquimod TFA salt
|
||
Gardiquimod diTFA,咪唑啉类似物TLR7/8激动剂,可特异性抑制巨噬细胞和活化外周血单个核细胞(PBMCs)的HIV-1感染。在浓度低于10 μM时,该化合物特异性激活TLR7。 | |||
T14035 |
3M-011
|
TLR | Immunology/Inflammation |
3M-011, a potent dual toll-like receptor TLR7/8 agonist and cytokine inducer, serves as a powerful adjuvant to radiotherapy, eliciting significant local and systemic immune responses. Additionally, it effectively inhibits H3N2 influenza viral replication in the nasal cavity and exhibits strong antitumor activity[1][2][3]. | |||
T79069 | TLR7/8 agonist 9 | ||
TLR7/8 agonist 9 (Compound 25a) 是一种能够增强PD-1/PD-L1阻断疗法抗肿瘤效果的化合物,主要用于癌症免疫疗法研究。它对hTLR7和hTLR8的EC50分别为40 nM和23 nM,显示出其对这两种受体的高亲和力以及潜在的抗肿瘤活性。 | |||
T61390 |
D18
|
||
D18 is an immune modulator that acts as a dual agonist for TLR7/8 (with EC50 values of 24 nM for hTLR7 and 10 nM for hTLR8, respectively). It enhances the expression of PD-L1 through epigenetic regulation, thereby increasing the sensitivity of tumors to PD-1/PD-L1 blockade. Additionally, D18 functions as a cytotoxin for ADC synthesis, specifically for the ADC HE-S2 [1]. | |||
T22091 |
Imiquimod hydrochloride
|
||
Imiquimod hydrochloride (R 837 hydrochloride)是一种免疫反应调节剂,是一种选择性的 toll 样受体 7 (TLR7) 激动剂。Imiquimod hydrochloride 在体内表现出抗病毒和抗肿瘤作用。Imiquimod hydrochloride 可用于外生殖器、肛周疣、癌症和 COVID-19 的研究。 | |||
T83895 |
NCI 126224
NSC 126224 |
||
NCI 126224 是一种 toll-like receptor 4 (TLR4) 的拮抗剂。它在 RAW 264.7 巨噬细胞中,选择性抑制由 TLR4 激动剂 LPS 引起的一氧化氮 (NO) 产生(IC50 = 0.31 µM),而对 TLR7/8 激动剂 R-848、TLR1/2 激动剂 Pam3CSK4 以及 TLR3 激动剂 poly(I:C) 的影响较小;但对于相同细胞中由 TLR2/6 激动剂 FSL-1 引起的 NO 产生,其抑制作用在 0.6 µM 时亦显现。此外,NCI 126224 在 BV-2 微胶质细胞的报告实验中抑制了 LPS 引起的 NF-κB 活性,并在 RAW 264.7 巨噬细胞中降低了 LPS 引起的 IL-1β 和 TNF-α 水平(IC50s = 5.92, 0.42, 和 1.54 µM,分别)。 |